The Kedrion Group, a developer of plasma derived products, has purchased Ortho-Clinical Diagnostics' Rho(D) immune globulin (Human) RhoGAM and Rho(D) Immune Globulin (Human) MICRhoGAM ultra-filtered Plus products, used for the prevention of Rh hemolytic disease of the newborn (HDN).
The acquisition will also include the purchase of Ortho Clinical’s subsidiary, Somerset Laboratories, a US FDA-licensed donation center that has collected blood plasma from the donor population used in the manufacturing process of the RhoGAM brand.
Kedrion Biopharma chief executive officer Paolo Marcucci said the company’s primary focus is to ensure that the tens of thousands of obstetricians and gynecologists, nurses, midwives, blood bankers and Rh-negative women who need it will continue to have the critical product as well as the service and education all have come to associate with the RhoGAM brand.
"Ortho Clinical Diagnostics will work with Kedrion to ensure a smooth transition so there are no changes in access to these life-saving products and services," Marcucci added.
"Acquisition of RhoGAM Brand, the legacy anti-D immune globulin, complements our portfolio of high-quality plasma-derived products, including those for the treatment of the hemolytic disease of the newborn, hemophilia and immune deficiencies."